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ABSTRACT
Purpose. To review the functional outcome and 
local recurrence rate of 29 patients who underwent 
segmental excision or intralesional curettage with 
adjuvant therapy for giant cell tumour (GCT) of bone.
Methods. Records of 17 men and 12 women (mean 
age, 30.17 years) who underwent segmental excision 
(n=18) or intralesional curettage followed by adjuvant 
therapy (n=11) for GCT of the femur (n=13), tibia 
(n=8), radius (n=6), or ulna (n=2) were reviewed. Nine 
of the patients had recurrent GCT of bone and had 
undergone segmental excision (n=6) or intralesional 
curettage (n=3) elsewhere. Functional outcome was 
evaluated using the Musculoskeletal Tumour Society 
(MSTS) scoring system. 
Results. The mean follow-up period was 6.4 (range, 
3–13.5) years. 14 patients were followed up for 3 to 
5 years, 12 for 5 to 10 years, and 3 for >10 years. Of 
20 patients with primary GCT of bone, 12 underwent 
segmental excision and had no recurrence, and 
8 underwent intralesional curettage, 2 of whom 
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developed local recurrence. Of the remaining 9 
patients with recurrent GCT of bone, there was 
one re-recurrence in each surgical option. Local 
recurrence was not associated with Campanacci 
grading or type of surgery. One of 18 patients 
with segmental excision and 3 of 11 patients with 
intralesional curettage had local recurrence (5.6% 
vs. 27.3%, p=0.139). The MSTS score was excellent 
in 7, good in 6, moderate in 2, fair in 2, and poor in 
one patient after segmental excision, whereas the 
score was excellent in 9 and good in 2 patients after 
intralesional curettage (p=0.206). The proportion 
of yielding an excellent outcome was higher after 
intralesional curettage (38.9% vs. 81.8%, p=0.0289). 
Nonetheless, the mean MSTS score of the 2 groups 
was comparable (74.17% vs. 86.36%, p=0.054).
Conclusion. Local recurrence of GCT was not 
associated with the surgical option. Nonetheless, 
intralesional curettage resulted in better functional 
outcome.
Key words: giant cell tumor of bone; neoplasm 
recurrence, local 
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introduction
Giant cell tumour (GCT) of bone is benign but 
locally aggressive and usually occurs around the 
metaphyseal area of long bones in contact with joint 
cartilage.1 It accounts for 4 to 5% of bone tumours and 
21% of benign tumours of bone.2 Surgical treatment 
options include segmental resection or intralesional 
curettage. The latter is associated with a higher 
local recurrence rate (18% to 50%).2–4 Curettage 
followed by adjuvant therapy using liquid nitrogen, 
phenol, or cement can decrease the recurrence rate. 
Resection with wide margins minimises recurrence 
but is associated with poorer functional results or 
complications in reconstruction.3 This study reviewed 
the functional outcome and local recurrence rate of 
29 patients who underwent segmental excision or 
intralesional curettage with adjuvant therapy for 
GCT of bone.
Materials and Methods
Records of 17 men and 12 women (mean age, 
30.17±10.98 years) who underwent segmental 
excision (n=18) or intralesional curettage followed by 
adjuvant therapy (n=11) for GCT of the femur (n=13), 
tibia (n=8), radius (n=6), or ulna (n=2) between 2000 
and 2011 were reviewed. Nine of the patients had 
recurrent GCT of bone and had undergone segmental 
excision (n=6) or intralesional curettage (n=3) 
elsewhere. The mean tumour size was 12.7 (range, 
4–21) cm. 
 According to the Enneking staging system,5 
tumour extension was intracompartmental in 22 
patients and extracompartmental in 7 patients. 
According to the Campanacci grading system,2 7 
tumours were classified as grade I (quiescent), 15 as 
grade II (active), and 7 as grade III (aggressive). Two 
grade I tumours, 9 grade II tumours, and all 7 grade 
III tumours were treated with segmental excision. 
Five grade I tumours and 6 grade II tumours were 
treated with intralesional curettage followed by 
adjuvant therapy (use of phenol and filling with 
polymethylmethacrylate). Surgical decision was 
based on whether the patient had prior surgery 
or recurrence as well as tumour size, soft tissue 
extension, and pathological fractures. 
 Functional outcome was evaluated using the 
Musculoskeletal Tumour Society (MSTS) scoring 
system.6 For the lower extremity, this comprises 
categories of pain, function, emotional acceptance, 
supports, walking, and gait. For the upper extremity, 
the latter 3 categories are hand positioning, dexterity, 
and lifting ability. Excellent was defined as 75% 
to 100%, good as 70% to 74%, moderate as 60% to 
69%, fair as 50% to 59%, and poor as <50%. Local 
recurrence was confirmed by radiography and 
magnetic resonance imaging.
 Functional outcomes of the 2 groups were 
compared using the Pearson Chi-squared test or 
Fisher’s exact test whenever appropriate. A p value 
<0.05 was considered statistically significant.
results
The mean follow-up period was 6.4 (range, 3–13.5) 
years. 14 patients were followed up for 3 to 5 years, 
12 for 5 to 10 years, and 3 for >10 years. Of 20 patients 
with primary GCT of bone, 12 underwent segmental 
excision and had no recurrence, and 8 underwent 
intralesional curettage with adjuvant therapy, 2 of 
whom developed local recurrence. Of the remaining 
9 patients with recurrent GCT of bone, there was one 
re-recurrence in each surgical option.
 Local recurrence was not associated with 
Campanacci grading or type of surgery. One of 18 
patients treated with segmental excision and 3 of 11 
patients treated with intralesional curettage had local 
recurrence (5.6% vs. 27.3%, p=0.139). There were one 
recurrence in each of grades 1 and 3 tumours and 2 
recurrences in grade 2 tumours (p=0.997).
 The MSTS score was excellent in 7, good in 6, 
moderate in 2, fair in 2, and poor in one patient after 
segmental excision, whereas the score was excellent in 
9 and good in 2 patients after intralesional curettage 
(p=0.206). The proportion of yielding an excellent 
outcome was higher after intralesional curettage 
(38.9% vs. 81.8%, p=0.0289). Nonetheless, the mean 
MSTS score of the 2 groups was comparable (74.17% 
vs. 86.36%, p=0.054).
discussion
GCT of bone is one of the most common tumours 
encountered by orthopaedic surgeons. The ubiquitous 
presence of giant cells in other unrelated entities 
and the presence of osteoid makes its diagnosis 
challenging, particularly when a needle core biopsy 
is used. There are no clinical, radiographic, or 
histological aspects that can predict the trend for 
recurrence or metastasis. Treatment options are based 
on retrospective analysis of non-randomised series 
from single or multiple institutions.7,8 The treatment 
goal is to balance adequate removal of tumour cells 
with function of the limb. Some studies consider 
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intralesional excision as the treatment of choice.9,10 
Others recommend curettage followed by adjuvant 
therapy to reduce the risk of recurrence,11,12 but 
adjuvant therapy has been considered unnecessary.9 
Adjuvants may remove remaining tumour cells 
after curettage by thermal (liquid nitrogen, methyl 
methacrylate) or chemical (phenol, hydrogen 
peroxide, alcohol) effects.7 The cavity can be left 
unfilled or be filled with cement or bone grafting. In 
the Scandinavian Sarcoma Group study involving 
294 patients, filling the cavity with cement after 
intralesional surgery resulted in a lower recurrence 
rate than no cementation (20% vs. 56%, p=0.001).11 
In contrast, in the Canadian Sarcoma Group study 
involving 186 patients, the use of adjuvants or 
filling the cavity was not associated with the risk of 
recurrence.4
 Resection with wide margins is usually reserved 
for aggressive stage 3 tumours when bone/joint 
destruction is too extensive or when sacrifice of 
bone results in better tumour control with minimal 
functional impairment (such as tumours located in 
the proximal fibula or distal ulna).7
 The recurrence rate is usually higher in stage 3 
tumours. However, in 327 patients at the Rizzoli 
Institute, radiological grading of tumours was not 
associated with treatment option or prognosis but was 
associated with the surgical margin.2 In contrast, in a 
multicentre study, the recurrence rate was associated 
with both Campanacci and Enneking staging.13
 Compared with joint resection, joint salvage has 
reported to achieve better functional outcome and a 
lower rate of non-oncological complications, but the 
difference is not significant).2,5,7,10
 Recurrence of GCT is usually not fatal but can 
lead to severe functional disability and poor quality 
of life secondary to repeat and radical operations. 
The overall risk of local recurrence has been reported 
to be 25 to 35% in earlier series of patients and 10 to 
20% in more recent series of patients at an institution.7 
In a review of 111 patients followed up for >2 years, 
the recurrence rate was 41% following curettage and 
bone grafting and 7.1% following wide excision.14 
One study reported a high recurrence of 75% after 
intralesional curettage without adjuvant therapy, 
but 0% recurrence after segmental excision.15 Two 
studies also reported 0% recurrence after segmental 
excision,16.17 but one of them reported 30.8% 
recurrence after intralesional curettage.16 In our series, 
the recurrence rate was 5.6% after segmental excision 
and 27.3% after intralesional curettage and adjuvant 
therapy (Table).
 For treatment of recurrence, resection with 
wide margins followed by reconstruction using 
modular prostheses is recommended.7 Nonetheless, 
in GCT in long bones treated with curettage and 
cementing, local recurrence is not associated with 
higher morbidity or greater risk of recurrence.18 Most 
cases of local recurrence can be successfully treated 
with further curettage and cementing, with a good 
outcome. In 183 patients treated with curettage for 
GCT, the recurrence rate was 25%.19
 Limitations of our study included the retrospective 
nature and inclusion of patients treated by different 
surgeons over a 10-year period.
conclusion
Local recurrence of GCT was not associated with 
surgical option. Nonetheless, intralesional curettage 
resulted in better functional outcome.
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Table
Comparison of recurrence of giant cell tumour of bone after segmental excision or intralesional curettage





















Becker et al.3 384 25.5 78 2 - 306 31.4 -
Errani et al.7 349 14.3 149 12 86.4 200 16.0 91.7
Oda et al.15 47 44.0 19 0 90.3 28 75.0 94.0
Guo et al.16 27 14.8 14 0 73.3 13 30.8 80.0
Rastogi et al.17 49 2.04 19 0 71.2 28 3.5 84.7
Our study 29 13.8 18 5.6 74.2 11 27.3 86.4
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